OncologyEducation· @OncEd · X·· 17 小时前评分70
正文 · 原文
Andrew Redfern, MD, on CCTG MA.40/FINER: ipatasertib + fulvestrant kept its PFS benefit but did not improve OS in ER+/HER2− mBC after a CDK4/6 inhibitor. #ESMO26
Watch now: https://bit.ly/4skqDBu
11 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：OncologyEducation · x.com